A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS

NCT06657079 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

119

Enrollment

OTHER

Sponsor class

Conditions

ARDS
Prevention and Control

Interventions

DRUG: combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
DRUG: Placebo

Sponsor

Damanhour University

Collaborators

[object Object]